Report cover image

Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 193 Pages
SKU # APRC20360449

Description

Summary

According to APO Research, the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market include Teva, Novartis, Merck, Pfizer, Amgen, SL Pharm, North China Pharmaceutical, Kyowa Kirin and Intas, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs, also provides the value of main regions and countries. Of the upcoming market potential for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Company

Teva
Novartis
Merck
Pfizer
Amgen
SL Pharm
North China Pharmaceutical
Kyowa Kirin
Intas
Hayao Group
GenSci
Dr. Reddy
Dong-A Socio
Chugai Pharmaceutical
Amoytop
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Type

Filgrastim
Lipefigrastim
Pefigrastim
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Application

Oncology
Blood Disease
Other
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs key companies, revenue, market share, and recent developments.
3. To split the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Granulocyte-Colony Stimulating Factor (G-CSF) Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Granulocyte-Colony Stimulating Factor (G-CSF) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs industry.
Chapter 3: Detailed analysis of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Dynamics
2.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Trends
2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Drivers
2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Opportunities and Challenges
2.4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Restraints
3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Company
3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Revenue Ranking in 2024
3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Company (2020-2025)
3.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Ranking (2023-2025)
3.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Manufacturing Base and Headquarters
3.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Product Type and Application
3.6 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Type
4.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Type Introduction
4.1.1 Filgrastim
4.1.2 Lipefigrastim
4.1.3 Pefigrastim
4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Type
4.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Type (2020-2031)
4.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type (2020-2031)
5 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Application
5.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Application Introduction
5.1.1 Oncology
5.1.2 Blood Disease
5.1.3 Other
5.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Application
5.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Application (2020-2031)
5.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application (2020-2031)
6 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Regional Value Analysis
6.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Region (2020-2031)
6.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Region: 2020-2025
6.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2020-2031)
6.3.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2020-2031)
6.4.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2020-2031)
6.5.2 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2020-2031)
6.6.2 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2020-2031)
6.7.2 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country, 2024 VS 2031
7 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Country-level Value Analysis
7.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Country (2020-2031)
7.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Country (2020-2025)
7.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.3.2 USA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.4.2 Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.6.2 Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.7.2 France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.7.3 France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.9.2 Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.10.2 Spain Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.11.2 Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.14.2 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.14.3 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.15.2 Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.17.2 India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.17.3 India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.18.2 Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.22.2 Chile Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.24.2 Peru Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.26.2 Israel Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.27.2 UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.29.2 Iran Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Teva
8.1.1 Teva Comapny Information
8.1.2 Teva Business Overview
8.1.3 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.1.4 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.1.5 Teva Recent Developments
8.2 Novartis
8.2.1 Novartis Comapny Information
8.2.2 Novartis Business Overview
8.2.3 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.2.4 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.2.5 Novartis Recent Developments
8.3 Merck
8.3.1 Merck Comapny Information
8.3.2 Merck Business Overview
8.3.3 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.3.4 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.3.5 Merck Recent Developments
8.4 Pfizer
8.4.1 Pfizer Comapny Information
8.4.2 Pfizer Business Overview
8.4.3 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.4.4 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.4.5 Pfizer Recent Developments
8.5 Amgen
8.5.1 Amgen Comapny Information
8.5.2 Amgen Business Overview
8.5.3 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.5.4 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.5.5 Amgen Recent Developments
8.6 SL Pharm
8.6.1 SL Pharm Comapny Information
8.6.2 SL Pharm Business Overview
8.6.3 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.6.4 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.6.5 SL Pharm Recent Developments
8.7 North China Pharmaceutical
8.7.1 North China Pharmaceutical Comapny Information
8.7.2 North China Pharmaceutical Business Overview
8.7.3 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.7.4 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.7.5 North China Pharmaceutical Recent Developments
8.8 Kyowa Kirin
8.8.1 Kyowa Kirin Comapny Information
8.8.2 Kyowa Kirin Business Overview
8.8.3 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.8.4 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.8.5 Kyowa Kirin Recent Developments
8.9 Intas
8.9.1 Intas Comapny Information
8.9.2 Intas Business Overview
8.9.3 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.9.4 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.9.5 Intas Recent Developments
8.10 Hayao Group
8.10.1 Hayao Group Comapny Information
8.10.2 Hayao Group Business Overview
8.10.3 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.10.4 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.10.5 Hayao Group Recent Developments
8.11 GenSci
8.11.1 GenSci Comapny Information
8.11.2 GenSci Business Overview
8.11.3 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.11.4 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.11.5 GenSci Recent Developments
8.12 Dr. Reddy
8.12.1 Dr. Reddy Comapny Information
8.12.2 Dr. Reddy Business Overview
8.12.3 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.12.4 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.12.5 Dr. Reddy Recent Developments
8.13 Dong-A Socio
8.13.1 Dong-A Socio Comapny Information
8.13.2 Dong-A Socio Business Overview
8.13.3 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.13.4 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.13.5 Dong-A Socio Recent Developments
8.14 Chugai Pharmaceutical
8.14.1 Chugai Pharmaceutical Comapny Information
8.14.2 Chugai Pharmaceutical Business Overview
8.14.3 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.14.4 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.14.5 Chugai Pharmaceutical Recent Developments
8.15 Amoytop
8.15.1 Amoytop Comapny Information
8.15.2 Amoytop Business Overview
8.15.3 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2020-2025)
8.15.4 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
8.15.5 Amoytop Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.